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a b s t r a c t
Balloon aortic valvuloplasty (BAV) is a well accepted modality of treatment in congenital
aortic stenosis in all age groups. Although in infants and children it is the modality of choice,
in adolescents and young adults, it is of debatable efﬁcacy.
Aim: To evaluate long-term results of aortic valvuloplasty particularly in adolescent and
adults (>12 years) and compare the outcome in other age groups that are <1 year and
between 1 are 11 years.
Setting: Tertiary referral center.
Patients: 165 consecutive patients treated at the median age of 9 years (1 day to 64 years). The
follow-up was up to 14 years (median 3 years). The whole cohort was divided into 3 age-
based subgroups: Group A (<1 year) n = 45, Group B (1 year–11 years) n = 52, and Group C (>12
years) n = 68. The characteristics of each subgroup were mutually compared.
Intervention: Percutaneous balloon valvuloplasty with mean (SD) balloon to annulus ratio
of 0.93.
Main outcome measures were repeat BAV, signiﬁcant aortic regurgitation (AR), and aortic
valve replacement/repair.
Results: The incidence of signiﬁcant AR from the whole cohort was 9.9% (8% moderate, 1.9%
severe); n = 16. Group A = signiﬁcant AR 9.5% (7.1% moderate, 2.4% severe), Group B = signif-
icant AR 11.3% (9.4% moderate, 1.9% severe), and Group C = signiﬁcant AR 9% (7.5% moder-
ate, 1.5% severe); p value = 0.99 (Group C vs Group A) and 0.92 (Group C vs Group B).
Repeat BAV rate was 13.3% (n = 22 out of 165 patients). Group A – n = 5 (11.9%), Group B –
n = 10 (18.2%), and Group C – n = 7 (10.3%). p Value = 0.78 (C vs A) and 0.19 (C vs B).
Surgery in follow-up was needed in n = 4 (2.4%), none in Group A, 2 patients in Group B
(3.6%), and 2 patients in group C (2.9%). Patients were followed up for a period of 14 years;
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Group A = up to 8 years, Group B = up to 13 years, and Group C = up to 14 years. Mean survival
probability after the procedure was 8 years (Group A = 6.5 years, Group B = 8.1 years, and
Group C = 9.9 years), and p value = 0.49 (A vs B), 0.23 (B vs C), and 0.4 (A vs C).
Conclusion: There is no statistical difference in the long-term outcome in the adults and
adolescents as compared to the children; thus BAV remains an obvious treatment of choice
with good long-term outcome.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1 6051. Introduction
Efﬁcacy of balloon aortic valvuloplasty (BAV) is well docu-
mented in children with congenital aortic stenosis with good
short-term results1–3 and increased incidence of restenosis, as
well as severe aortic insufﬁciency reinterventions in mid-term
follow-up.4,5 Long-term results have shown 20% restenosis
rate and a 21% incidence of signiﬁcant aortic insufﬁciency
2–12 years after the procedure.6 The data regarding the
outcomes of BAV in grown-up patients are scarce.
2. Material and methods
The purpose of our study was to evaluate long-term results of
percutaneous BAV in a large cohort of patients and comparing
the results of BAV in adults and adolescents with different age
groups of the similar population.
All the patients who underwent balloon aortic valvotomy
from May 2005 to May 2014 were included in the study
(Table 1). For ease of analysis, the whole cohort of patients was
divided into three mutually exclusive groups: Group A: up to 1
year of age, Group B: 1–11 years of age, and Group C: 11 years
and above.
Peak-to-peak gradient for the ease of analysis was divided
into <50 mmHg and >50 mmHg for the ease of statistical
analysis, as per the recommendations. All the patients had a
complete clinical and echocardiographic examination before
the valvuloplasty.
2.1. Echocardiography
Aortic valve gradient was assessed by continuous and pulsed







n 45 52 
Mean  Standard
deviation
Age (years) 0.115  0.2 6.
Weight (kilograms) 4.0  1.8 12.
Median (range, kg) Age (years) 0.0 7.
Weight (kilograms) 3.3 (2.2–10.2) 8.approach, and the highest gradient measured was accepted.
Peak instantaneous gradient was calculated from maximum
ﬂow velocity and mean gradient by a time–velocity integral.
Aortic regurgitation (AR) was assessed by color ﬂow mapping
and pulsed Doppler and scored on a ﬁve-grade scale: grade 1–4
(1 – no regurgitation; 2 – mild; 3 – moderate; 4 – severe, reverse
diastolic ﬂow in the abdominal aorta). Left ventricular ejection
fraction (LVEF) was calculated using Simpson's rule in apical
4-chamber view. LVEF = 55% was taken as normal. The aortic
annulus diameter and the morphology of the aortic valve were
assessed by means of two-dimensional imaging from the
parasternal long- and short-axis views.
2.2. Valvuloplasty
Informed consent to undergo the procedure was signed by
parents or patients as appropriate. The risks of the procedure
and long-term issues of AR and restenosis were explained. The
valvuloplasty was performed from the percutaneous femoral
arterial approach in all but 5 patients. In 1 neonate (Group A),
carotid cut-down was used, as femoral access was not feasible.
In 3 patients in Group B and 1 patient in Group C, transseptal
puncture was done to cross the aortic valve as aortic valve could
not be crossed retrogradely. Echocardiography measurements
of the aortic annulus were used to decide the balloon diameter.
The chosen balloon diameter was 90% or equal to the aortic
valve annulus. If adequate results were not obtained, then the
balloon with biggest diameter was used with an attempt not to
exceed 100% of annular diameter. Also the calciﬁed aortic valve
of the elderly was excluded and not taken for BAV.
2.3. Follow-up
The patients were followed up by clinical examination and
complete echocardiographic evaluation a day after theowing the age (in years) and weight (in kilogram), with their




(12 years and above)
68 165
885  2.8 20.6  9.7 10.9  10.8
4  10.3 43.6  18.8 23.6  22.2
0 18.5 9.0
7 (2.3–43) 40.0 (9–87) 17.0
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1606procedure, at discharge from the hospital, a month after
discharge, and later at six month to yearly intervals according
to the residual ﬁndings. The follow-up period ranged from
6 months to 14 years (median 3 year). Total patients lost to
follow-up were n = 34 (20.6%); Group A n = 4 (12.9%), Group B
n = 9 (20.9%), and Group C n = 21 (35%). All others had a
complete clinical and echocardiographic evaluation in our
outpatient clinic. Thus, follow-up data were available for 131
(79.3%) patients. In the patients lost to follow-up, the last
available echocardiographic data were used for analyses,
and in the patients who required surgery, the last echocardi-
ography data before surgery were used.
In the follow-up of the patients, the echocardiographic
records were reviewed for the determination of Doppler
gradients, need for repeat balloon aortic valvotomy, and
need for surgery (AVR). The outcome parameters of the
study were repeat BAV, need for surgery, and signiﬁcant AR
(grade 3 and 4), as detailed above. The outcome parameters
were analyzed in the three groups with respect to age, balloon
aortic annulus ratio, Z score, weight of the patient, LV
dysfunction at the time of the presentation, pregradient of
the catheterization, and associated lesions (bicuspid aortic
valve, unicuspid aortic valve, associated lesions, such as
ventricular septal defect (VSD), atrial septal defect (ASD),
patent ductus arteriosus (PDA), coarctation of aorta, presence
of mitral regurgitation (MR), and mitral stenosis (MS)).
Improvement of LV function was analyzed in the patients
with decreased LV function and possible factors that could
have contributed were looked at.
2.4. Statistical analysis
SPSS version 17 was used for statistical analysis. Continuous
variables are presented as mean  SD and categorical vari-
ables are presented as percentages. Differences between
continuous variables were assessed by Student t test. Paired
tests were analyzed by paired Student t test. Categorical
variables were compared using the chi-square test or Fisher
exact test as indicated. Signiﬁcance was set at p < 0.05.
Cumulative survival curves were constructed using the
Kaplan–Meier method and compared by the log-rank test.
The Cox proportional hazard regression method was used to
examine the univariable association of clinical, catheteriza-
tion, and echocardiographic variables with event-free survival.
Multivariable associations within these same groups were also
evaluated. All continuous variables were measured in their
original scale.Table 2 – Table showing the balloon–annulus ratio and Z score
group BAR = 0.76–1.08 (mean 0.93 W 0.24).
Age groups Balloon–annulus ratio 
Mean Median 
<1 Year (Group A) 0.98  0.45 0.88 
1–11 Years (Group B) 0.89  0.11 0.92 
≥12 Years (Group C) 0.91  0.06 0.93 
Total 0.93  0.24 0.92 3. Results
There were a total of n = 165 patients over the period; Group A
n = 45 (27.2%), Group B n = 52 (31.5%), and Group C n = 68
(41.2%). All the patients were analyzed with respect to the
three subgroups (A, B, and C) (Table 1).
In Group A, the mean age at the time of valvuloplasty was
1.2 months (range 0–1 years). There were 22% newborns
under 4 weeks of age (13.3% of the total cohort and 48% of the
total Group A cohort). Group B included patients of 1–11 years
of age, n = 52 (31.5%); the mean age at the time of valvuloplasty
was 6.8 years (range = 1–11 years). Group C included patients
of ≥12 years n = 68 (41.2%); the mean age at the time of
valvuloplasty was 20.6 years (range = 12–24 years) (Table 1).
Balloon–annulus ratio (bar) and Z scores of annulus are
elaborated in Table 2.
3.1. Catheter gradient
The immediate change in peak-to-peak catheter gradient was
compared in three subgroups (cut-off peak-to-peak gradient
50 mmHg). For Group A, 94.3% (n = 42/45) patients had a
gradient change, while 5.7% (n = 2) of the patients had gradient
that continued to be more than 50 mmHg. In follow-up, out of
the 5.7% (n = 2) patients, 1 underwent repeat BAV. For Group B,
93.2% (n = 48/52) patients had a gradient change, while 6.8%
(n = 3) of the patients had gradient that continued to be more
than 50 mmHg. For Group C, 88.1% (n = 59/68) patients had a
gradient change, while 11.9% (n = 7) of the patients had
gradient that continued to be more than 50 mmHg. In
follow-up, out of the 7 patients, 2 had repeat BAV. p Value
for Group B vs A is 0.51, and Group C vs A is 0.47. The
percentage fall in gradient for each group was as follows:
Group A had a change of 57.6%  20.6% in mean gradient;
Group B had a change of 61.6%  22.1% in mean gradient;
Group C had a change of 64.2%  20.4% in mean gradient.
There was no signiﬁcant difference of p value between the
three groups (A vs B <0.0001, B vs C <0.0001, A vs C <0.001).
3.1.1. LV dysfunction
LV dysfunction at the time of presentation was present in
66.7% of patients in Group A (n = 28), 40.7% in Group B (n = 22),
and 10.9% in Group C (n = 7). This accounted for 35.5% of the
whole cohort of BAV patients.
Follow-up for each subgroup A, B, and C will be discussed
with respect to three outcome parameters: repeat BAV, needs for the 3 groups of patients: A, B, and C. (For the whole
Z-score
n Mean Median
34 0.77  0.1 0.73
46 1.05  0.3 1.0
59 1.68  0.26 1.68
139 1.25  0.46 1.26
Table 3 – The distribution of aortic insufficiency (AR) with their grading, repeat BAV and surgery for the 3 groups of patients:
A, B, and C.
Complications Age groups Total






(12 years and above)
AR (n and % within each
age group)
1 (None) 15 (35.7%) 22 (41.5%) 21 (31.3%) 58 (35.8%)
2 (Trace) 6 (14.3%) 7 (13.2%) 10 (14.9%) 23 (14.2%)
3 (Mild) 17 (40.5%) 18 (34%) 31 (44.8%) 65 (40.1%)
4 (Moderate) 3 (7.1%) 5 (9.4%) 5 (7.5%) 13 (8%)
5 (Severe) 1 (2.4%) 1 (1.9%) 1 (1.5%) 3 (1.9%)
Total 42 53 67 162
Follow-up (n and % within
each age group)
Repeat BAV 5 (11.9%) 10 (18.2%) 7 (10.3%) 22 (13.3%)
Surgery 0.0 (0.0%) 2 (3.6%) 2 (2.9%) 4 (2.4%)
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1 607for surgery, and AR (Table 3). Further, the three outcome
parameters would be discussed, including the factors inﬂu-
encing each parameter in the three subgroups (A, B, and C), viz.
age, balloon aortic annulus ratio, Z score, weight of the patient,
LV dysfunction at the time of the presentation, predilatation
gradient, peak-to-peak gradient of the catheterization, and
associated lesions (bicuspid aortic valve, unicuspid aortic
valve, VSD, ASD, PDA, coarctation of aorta, presence of MR and
MS).
3.2. Repeat BAV
Repeat BAV was required in 5 patients in Group A (11.9%),
10 patients in Group B (18.2%), and 7 patients in Group C
(10.3%). p Value = 0.78 for (Group A vs C), and p = 0.196 for
(Group B vs C) (Table 3).
Of those requiring repeat BAV, 15.8% (n = 9) patients had LV
dysfunction at the time of presentation (Table 4). Of these,
44.4% (n = 4) were in Group A, 44.4% (n = 4) were in Group B, and
11.1% (n = 1) were in Group C. These patients continued to
have LV dysfunction in follow-up.
All the patients taken for BAV had no signiﬁcant AR
(ranging from grade 1–2) preprocedure. Group A had grade
1 – 40.1% and grade 2 – 59.9%. Group B had grade 1 – 38.4% and
grade 2 – 61.7%. Group C had grade 1 – 42.1% and grade 2 –79.7%.
Balloon–annulus ratio for those undergoing repeat BAV was
1.09 (0.6) as compared to patients who did not have repeat
BAV, who had BAR of 0.92 (0.05).
3.3. Gradient change
Mean predilatation gradient was 70  31 mmHg and post-
dilatation gradient was 30.8  22 mmHg in the patients whoTable 4 – The profile of patients with ventricular dysfunction (le
chamber view by Simpsons method) in follow-up.
Follow-up  LV_
Follow-up (n and % within each age group 1 (Repeat BAV) 
2 (Surgery) underwent repeat BAV, as compared to those who did not
have repeat BAV, who had a mean predilatation gradient of
85  30.5 mmHg and postdilatation gradient of 23  15.5
mmHg. Thus, those who had signiﬁcant change in gradient
from pre- to postdilatation had less chance of repeat BAV than
those who had less change in gradient.
For Group A, 94.3% (n = 42/45) of the patients had
predilatation gradient >50 mmHg that decreased to post-
dilatation gradient <50 mmHg, while 5.7% (n = 2) of the
patients had gradient that continued to be more than 50
mmHg. In follow-up, out of these 2 patients, 1 had repeat BAV.
For Group B, 93.2% (n = 48/52) of the patients had pregra-
dient >50 mmHg that decreased to postgradient <50 mmHg,
while 6.8% (n = 3) of the patients had peak gradient that
continued to be more than 50 mmHg. In follow-up, none of
these 3 patients had a repeat BAV or surgery.
For Group C, 88.1% (n = 59/68) of the patients had pregra-
dient >50 mmHg that decreased to postgradient <50 mmHg,
while 11.9% (n = 8) of the patients had gradient that continued
to be more than 50 mmHg. In follow-up, out of these 7 patients,
2 had repeat BAV.
p value = 0.476 for (Group A vs C), and p = 0.510 for (Group B
vs C).
All the patients requiring repeat BAV or surgery had
features of effort intolerance.
3.4. Aortic insufﬁciency (Table 3)
AR was divided into 4 groups, 1–4 (1 – none, 2 – mild, 3 –
moderate, 4 – severe), for the ease of outcome analysis.
Group A had 9.5% incidence of signiﬁcant AR (7.1%
moderate n = 3, 2.4% severe n = 1), while most patients had
no AR (35.7%, n = 16) or mild AR (55%, n = 25).ft ventricular ejection fraction <55% measured in apical four
dysfunction
LV_dysfunction Total
1 (Present) 2 (Absent)
Count 9 (15.8%) 13 (12.6%) 22 (13.8%)
Count 2 (3.5%) 2 (1.9%) 4 (2.5%)
Table 5 – The survival for the 3 groups of patients (see also Kaplan–Meier curve).
Duration of follow-up 2 Years 4 Years 6 Years 8 Years 10 Years 12 Years 14 Years
Age groups <1 Year 86% 78.5% 70.8% 45%
1–11 Years 79.3% 63.6% 56% 50.2% 41.8% 20.2%
≥12 Years 92.3% 89.9% 86.2% 52.9% 44% 31% 0%
Survival table showing cumulative proportion surviving at the time.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1608Group B had 11.3% incidence of signiﬁcant AR (9.4%
moderate n = 5, 1.9% severe n = 1), while most patients had
no AR (41.5%, n = 22) or mild AR (47.2%, n = 18).
Group C had 9.9% incidence of signiﬁcant AR (7.5%
moderate n = 5, 1.5% severe n = 1), while most patients had
no AR (32%, n = 22) or mild AR (59.7%, n = 40).
p value = 0.99 for (Group A vs C), and p = 0.92 for (Group B
vs C).
The bicuspid aortic valve was compared and was not
observed to have impact on the degree of AR or falling gradient.
The maximum impact observed was when the postgradient
was reduced signiﬁcantly; probably the signiﬁcant change in
gradient was at the cost of signiﬁcant AR.
3.5. Relation between signiﬁcant AR and balloon annulus
Ratio in Group A, the mean balloon–annulus ratio for patients
having signiﬁcant AR is 0.8, in Group B it is 0.94, and in Group C
it is 0.91. Thus, there was statistically no difference between
the BAR and AR. This was not an age-dependent variable. And
thus, balloon size was not an attributable cause of signiﬁcant
aortic insufﬁciency when compared between the groups.
Also a strong correlation existed with the presence of
associated risk factors for AR. Presence of PDA (63.7%) and
coarctation of aorta (25%) were invariably associated with the
presence of signiﬁcant AR.Fig. 1 – Kaplan–Meier curve showing the follow-up of the 3 subs
labeled by the term ‘‘censored’’ signifies the events: either repeSurgery (Tables 3 and 5) in follow-up was observed in 2.4%
(n = 4), none in Group A, 2 patients in Group B (3.6%), and 2
patients in Group C (2.9%), and it was observed over a follow-
up period of Group A = 0–8 years, Group B = up to 13 years, and
Group C = up to 14 years. Mean survival probability after the
procedure was 8.9 years (Group A = 6.5 years, Group B = 8.1
years, and Group C = 9.9 years). p Value = 0.49 (A vs B), 0.23 (B vs
C), and 0.4 (A vs C) (Figs. 1 and 2).
4. Discussion
Our study presents a single institution's experience with 165
consecutive patients with congenital aortic stenosis treated by
percutaneous balloon valvuloplasty with the aim to compare
the outcomes in three subsets of patients with hypothesized
different outcomes as per age, and these subsets of patients
were subsequently followed up for long-term outcomes up to
14 years. The institution is a tertiary care referral center for a
large subset of population of the country. In all the patients
who underwent valvuloplasty, it was the initial method used.
4.1. The study design discussed
The purpose of having divided the patients into three
groups was essentially to compare the outcomes of Group Cets of patients A, B, and C as per the age group. + sign as
at BAV or surgery.
Fig. 2 – Kaplan–Meier curve showing the follow-up of the 3 subsets of patients as a single cohort. Mean (SEM) survival
probability, 14.4 years after the procedure, was 0.89 (0.02) and mean (SEM) probability of surgery-free survival was 0.50 (0.08).
+ sign as labeled by the term ‘‘censored’’ signifies the events: either repeat BAV or surgery.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1 609(i.e. patients above 11 years of age) with those of the Group A
and Group B. BAV remains the procedure of choice for the
infants in Group A and Group B. The same is essentially
because of the need of a more invasive repeated surgical
procedure whenever performed in this particular age group.
There is in general high degree of inclination for surgical
intervention in young and adolescents age groups (Group C),
having achieved a larger annulus size and less chance of a
repeated surgery for the valve mismatch. Also, few would
consider that BAV is just a bridge to surgery to buy time. The
inclination for the surgical group stems from the popular
thinking that most of the patients of the aortic valve disease
would end up on the surgical table. Thus, Group C remains a
subject of contention between the surgical proponents and
interventional cardiologist. The present study was essentially
planned with this aim to reevaluate the outcomes of this group
of patients with those in other age groups, and to look at their
long-term outcome.
4.2. Why the division into age groups
There are a number of studies that have evaluated the patients
from 0 years to adult age who underwent BAV as a single
cohort.10,11 Also there are a number of studies that discuss the
advantages of using the procedure in patients who are
unsuitable for surgical correction 12–14 with good long-term
outcome. There is still a lack of available literature that
exclusively looks at young adult and adolescents, with the aim
to evaluate the outcomes of BAV, in an age group that is
otherwise suitable for aortic valve replacement in view of
generally adequate annulus size with or without Konnos. A
few studies showed high incidence of surgery after BAV.12,13In the present study, all the patients were enlisted and
subsequently analyzed retrospectively with respect to the
presentation of the patients and risk factors. Risk factors
compared in the study for each group was ventricular
dysfunction at the time of presentation, degree of aortic
insufﬁciency at the time of presentation, and associated risk
factors because of sick presentation of these subgroups of
patients. LV dysfunction was present in 44.4% of Group A
patients as compared to only 11.1% in Group C, as Group A
always represents a sicker group of patients. So although the
need of repeated BAV correlated with the ventricular dysfunc-
tion, statistically it did not impact the difference in long-term
outcome when compared for all the three groups ( p val-
ue = 0.751 for patients undergoing repeat BAV with and
without LV dysfunction). Also, in consistent with the observed
studies, the ventricular dysfunction improved signiﬁcantly in
all the age groups after BAV.15 Pedersen et al. have demon-
strated the same even in the elderly population.16,17 All the
patients in the present study underwent BAV using low-proﬁle
Tyshak II balloon, which have shown good results in various
studies.18 Retrograde technique was used in most of the
patients, while in 8 patients antegrade transseptal technique
was also used.19 Innoue was used in none of our patients for
BAV till data were analyzed. Rapid ventricular pacing20 was
used as a protocol in all of our patients in Group C and a few
in Group B.
Aortic insufﬁciency was divided into 4 grades as per the
standard recommendations. Signiﬁcant AR (i.e. grade 3 or 4),
i.e. moderate or severe AR, was observed in 9.9% of the total
cohort of our patients with no statistical difference between
the three groups, p value = 0.99 (C vs A) and 0.92 (C vs B).
Interestingly, the valve morphology did not impact the degree
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1610of AR in any of our subgroups (a observation seen in few other
studies),10,11 but we believe this is because of the presence
of even distribution of the bicuspid aortic valve patients in
all the three groups, making the difference between them
statistically insigniﬁcant. Associated lesions, such as PDA (27%
of AR) and coarctation (25% of AR), were observed to have
strong association with the presence of signiﬁcant AR in our
study.
Our restenosis rate was comparable and aortic insufﬁciency
rate and surgical rate were lower than many other reported
studies.4–20 O Reich et al.4 followed up over a period of 15 years
showed restenosis rate of 16.7% (n = 45) and signiﬁcant
insufﬁciency in 22.3% (n = 60); surgery was needed in 20.1%
(n = 54), and ‘‘valvuloplasty failure’’ occurred in 41.6% (n = 112)
of patients. But we believe that they looked at the full cohort
of patients from 0 to 23 years as a single subset, which is a
wide spectrum of patients and probably the subgroups should
be subdivided into age groups to evaluate the age-related
discrepancies in evaluation (as done in our study).
Division into subgroups really helps to distinguish the
impact of age on various subgroups. There are only a few
studies that evaluate the patients on the age-related aspects.
Balmer et al. in their cohort of 70 patients (up to 16 years of age)
divided them into less than 3 months and more than 3 months,
and showed that pressure gradient dropped signiﬁcantly with
the intervention and increased mildly at follow-up. Freedom
from AR was initially lower in group <3 months (75% vs 90%
after one month), but after two years, the difference between
the two groups was not signiﬁcant (50% vs 61%). Thus their
observation is similar to our ﬁndings.
The issues that decide the long-term AR still remain
controversial. In our study, though it was not intended to
evaluate the risk factors for AR, we observed that neither the
valve morphology nor the presence of bicuspid aortic valve
was a signiﬁcant risk factor for AR. Similar ﬁndings were
shown by few other studies,10–14 although the associated
lesions when present were found to have a statistically
signiﬁcant correlation with presence of AR.
Repeat BAV rate was 13.3% (n = 22 out of 165 patients).
Repeat BAV was required in 5 patients in Group A (11.9%), 10
patients in Group B (18.2%), and 7 patients in Group C (10.3%). p
Value = 0.78 for (Group C vs A), and 0.19 for (Group C vs B).
Mean pregradient was 70  31 mmHg and postgradient was
30.8  22 mmHg in the patients who underwent repeat BAV,
as compared to those who did not have repeat BAV, who had a
mean pregradient of 85  30.5 mmHg and postgradient of
23  15.5 mmHg. Thus, those who had signiﬁcant change in
gradient from pre to post had less chance of BAV than those
who had less change in gradient. Change in gradient was 57.6%
for Group A, 61.7% for Group B, 64.2% for Group C, and 61.7% for
the whole cohort of patients. Signiﬁcant decrease in gradients
have been shown by many other studies.4–8,10,11 Similarly, as
others,4–20 we have obtained an effective reduction of gradient
by valvuloplasty but the gradient on average did not increase
over the follow-up period. In our study, there was a statistically
signiﬁcant reduction in gradient in each of the three subgroups
but there was no statistical difference between the change in
gradients between the three groups of patients A, B, and C and
hence the BAV procedure is equally efﬁcacious in all the three
with no statistical difference between the subgroups.Higher incidence of surgery than our group has been shown
in various studies. 15%, n = 42, of their 272 patients of Maskatia
et al. underwent aortic valve surgery. Our subgroup of patients
had no statistical difference between the three groups with
5 patients undergoing surgery in the whole cohort. Of the
patients who underwent the surgery, i.e. aortic valve replace-
ment, indication was the same as in their study, i.e.
signiﬁcantly increased aortic insufﬁciency. Understandably,
none of the patients with signiﬁcant residual AS underwent
surgery as these are always considered for a repeated BAV.
None of our patients warranted AVR because of associated
cardiac surgery for other valve replacement. None of the
patients in group 1 underwent a surgery in follow-up, and
probably they still have not achieved that age that makes them
a suitable candidate for AVR, although we agree that none of
them required an aortic valve repair as well. In spite of this, the
difference between the groups was not statically signiﬁcant.
Also, as compared to other studies, we had a lot of patients
who did not warrant surgery. This could imply improved
Indian results with BAV as compared to other subgroups of
patients. The lost to follow-up data could have squeaked the
results, but loss to follow-up is not signiﬁcant between the
groups.
For the three subgroups of patients, there is signiﬁcant
difference in annulus diameter with Group A having smaller
annulus diameter compared to peers. Group C is having
comparatively similar annulus diameter compared to peers,
and still the results of BAV are comparable in both the groups.
4.3. Follow-up (Table 5)
The follow-up period ranged from 0 days to 14 years (median 3
years). Total patients lost to follow-up were n = 34 (20.6%); in
Group A n = 4 (12.9%), Group B n = 9 (20.9%), and Group C n = 21
(35%), with no statistical difference between the three groups.
All had a complete clinical and echocardiographic evaluation
in our outpatient clinic. The last end point was especially
rigorous and included all the signiﬁcant residual ﬁndings or
need for surgery or death. Indeed, studies that compared
valvuloplasty with surgical valvotomy have had almost
identical results for these methods.8 In such a situation, the
lower treatment costs and higher patient comfort speak in
favor of balloon valvuloplasty.
4.3.1. Limitations
The present study has been done on a large cohort of patient
with the aim to look at the outcome of the patients in adults
and adolescents, comparing them with the outcomes in the
proven subsets of children; but we must realize that each
subset of population has its own selective features and the
adolescents are not grown-up children or miniaturized adults.
Thus, the gradients that stand true for a small child may not be
truly suitable for an active adult or adolescent population. The
ventricular dysfunction was not graded in the present study
and hence it would be interesting to look at the change in the
ventricular function over time from a prospective cohort of
patients. Less number of patients that required surgery
although speaks volumes about the efﬁcacy of BAV, but the
statistical difference between the three groups could be
inﬂuenced and non representative being too small a number
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 0 4 – 6 1 1 611undergoing surgery. Technically, we expected more patients in
Group C as compared to Group B or A for surgery. Our study
had a large population of bicuspid aortic valves and thus the
outcomes were skewed toward the same. Also, the incidence
of bicuspid aortic valve was similar in the 3 groups of patient;
this nulliﬁed the effect of the valve morphology on each
selective subgroup. But we are not in a position to compare the
outcome of valve morphology on long-term outcome and that
was not a part of the study too.
5. Conclusion
There being no statistical difference in the long-term outcome
in the adults and adolescents as compared to the children,
who are considered more suitable for BAV, the BAV remains an
obvious treatment of choice with good long-term outcome as
demonstrated by this study.
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